MedTrace Logo

Allofit® IT With HXPE in Total Hip Arthroplasty

NCT03672929 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 197

Last updated 2026-01-27

Study results available
· View outcomes & findings →

Summary

The study design is a multi-center, prospective, non-controlled, consecutive cohort postmarket clinical follow-up study to obtain survival and outcome data on the Allofit IT Shell in combination with Longevity Liners in primary total hip arthroplasty.

Conditions

  • Avascular Necrosis
  • Osteoarthritis, Hip
  • Inflammatory Arthritis
  • Post-Traumatic Osteoarthritis of Hip

Sponsors & Collaborators

  • Zimmer Biomet

    lead INDUSTRY

Principal Investigators

  • Emilie Rohmer · Zimmer Biomet

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-05
Primary Completion
2025-07-03
Completion
2025-07-03

Countries

  • Austria
  • France
  • Germany
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03672929 on ClinicalTrials.gov